The information on this page is for informational purposes only and does not constitute medical advice. Consult your genetic counselor or specialist physician for treatment decisions.

The Fondazione Genomic SARS-CoV-2 Study COVID-19

Plain-language summary

This study investigates the genetic factors that may lead to respiratory failure in people with COVID-19 (SARS-CoV-2 infection). It included SARS-CoV-2-positive patients with severe lung involvement, blood donors exposed to the virus, and healthy controls. It was carried out as a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase
Not Applicable
Status
Completed
Sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Intervention
genetic determinants to develop respiratory failure, genetic determinants to develop respiratory failure, genetic determinants to develop respiratory failure
Start date
3/23/2020
Estimated completion
5/31/2023
Countries
Italy

Related genes

Locations

  • Milan, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Cohort 1 inclusion criteria:

* SARS-CoV-2 positive patients (no age limit) with severe pulmonary compromise, hospitalized with failure respiratory that requires support of any kind
* Signature of informed consent

Cohort 2 inclusion criteria:

* Blood donors (18-70 years old) who donated between 24/02/2020 and 31/12/2021
* exposure to the SARS-CoV-2 virus confirmed by viremia positive and presence of IgG/IgM
* Signature of informed consent

Cohort 3 inclusion criteria:

Healthy controls available from previous studies (n=5,000, ages 14-80 years), whose data are already available for genetic association analyses within the Kiel University database.
This is not medical advice. Consult your specialist.
View the official record on ClinicalTrials.gov →